Research

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

Kwok M Ho¹ , Jeffrey Lipman², Geoffrey J Dobb³ and Steven AR Webb⁴

¹Consultant Intensivist, Department of Intensive Care, Royal Perth Hospital, Australia

²Professor and Head of the Department, Department of Intensive Care Medicine, Royal Brisbane Hospital, University of Queensland, Australia

³Acting Head of the Department, Department of Intensive Care, Royal Perth Hospital, Australia and Associate Professor, School of Medicine and Pharmacology, University of Western Australia, Australia

⁴Consultant Intensivist, Department of Intensive Care, Royal Perth Hospital, Australia and Senior Lecturer, School of Medicine and Pharmacology, University of Western Australia, Australia

author email corresponding author email

Critical Care 2005, 9:R710-R717doi:10.1186/cc3883

Published:	25 October 2005

See related letter http://ccforum.com/content/10/1/402

Abstract

Introduction

High-risk surgical patients are at increased risk of fungal infections and candidaemia. Evidence from observational and small randomised controlled studies suggests that prophylactic fluconazole may be effective in reducing fungal infection and mortality. We evaluated the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients.

Methods

Randomised controlled studies involving the use of fluconazole in immunocompetent high-risk surgical patients from the Cochrane Controlled Trial Register (2005, issue 1) and from the EMBASE and MEDLINE databases (1966–30 April 2005), without any language restriction, were included. Two reviewers reviewed the quality of the studies and performed data extraction independently.

Results

Seven randomised controlled studies with a total of 814 immunocompetent high-risk surgical patients were considered. The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06–0.72, P = 0.01; I² = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I² = 0%), but was associated with only a trend towards a reduction in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I² = 7%). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, P = 0.004; I² = 0%). The proportion of patients colonised with or infected with fluconazole-resistant fungi was not significantly different between the fluconazole group and the placebo group (RR = 0.66, 95% CI = 0.22–1.96, P = 0.46; I² = 0%).

Conclusion

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients is associated with a reduced incidence of candidaemia but with only a trend towards a reduction in hospital mortality.